Fixed ratio dosing of pramlintide with regular insulin before a standard meal in patients with type 1 diabetes.

Riddle MC, Yuen KC, de Bruin TW, Herrmann K, Xu J, Öhman P, Kolterman OG

Diabetes, obesity & metabolism8 Jul 2015Cited by 25 (Europe PMC)

PMID26040429PMCIDPMC4758401DOI10.1111/dom.12504PepBankPUB-26040429

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with type 1 diabetes, all pramlintide ratios reduced postprandial glucose increments by more than half versus placebo.
In plain wordsIn type 1 diabetes, all pramlintide ratios reduced glucose rises by more than half versus placebo.
Peptide
Pramlintide (Symlin)
Outcome
DecreasePostprandial glucose increment
Study
n: not reported in source
Comparator
Placebo with regular human insulin
Outcome group
Glycemic control · Metabolic and weight
Studied dose
6, 9 or 12 mcg/unit insulin · injectionAs given in this study (human).
Measurements
Glucose increment reduction
> 50%
all ratios, 0-3 h
Source sentences
Summary
All ratios reduced 0-3-h glucose and glucagon increments by >50%.
2 context sentences(design, population, supporting numbers)
Summary · context
Patients with type 1 diabetes were enrolled in a randomized, single-masked, standard breakfast crossover study using regular human insulin injected simultaneously with pramlintide 6, 9 or 12 mcg/unit insulin or placebo.
Summary · context
Insulin dosage was reduced by 30% from patients' usual estimates.
Report a problemFND-2604042901
02HumanRandomized controlled trialEfficacy outcome
In patients with type 1 diabetes, all pramlintide ratios reduced postprandial glucagon increments by more than half versus placebo.
In plain wordsIn type 1 diabetes, all pramlintide ratios reduced glucagon rises by more than half versus placebo.
Peptide
Pramlintide (Symlin)
Outcome
DecreasePostprandial glucagon increment
Study
n: not reported in source
Comparator
Placebo with regular human insulin
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
6, 9 or 12 mcg/unit insulin · injectionAs given in this study (human).
Measurements
Glucagon increment reduction
> 50%
all ratios, 0-3 h
Source sentences
Summary
All ratios reduced 0-3-h glucose and glucagon increments by >50%.
2 context sentences(design, population, supporting numbers)
Summary · context
Patients with type 1 diabetes were enrolled in a randomized, single-masked, standard breakfast crossover study using regular human insulin injected simultaneously with pramlintide 6, 9 or 12 mcg/unit insulin or placebo.
Summary · context
Insulin dosage was reduced by 30% from patients' usual estimates.
Report a problemFND-2604042902
03HumanRandomized controlled trialSafety outcome
In patients with type 1 diabetes receiving pramlintide with insulin, no hypoglycaemia occurred.
In plain wordsNo low blood sugar occurred in patients receiving pramlintide with insulin.
Peptide
Pramlintide (Symlin)
Outcome
Not applicableHypoglycaemia
Study
n: not reported in source
Outcome group
Adverse events · Metabolic and weight
Studied dose
6, 9 or 12 mcg/unit insulin · injectionAs given in this study (human).
Source sentences
Summary
No hypoglycaemia occurred.
2 context sentences(design, population, supporting numbers)
Summary · context
Patients with type 1 diabetes were enrolled in a randomized, single-masked, standard breakfast crossover study using regular human insulin injected simultaneously with pramlintide 6, 9 or 12 mcg/unit insulin or placebo.
Summary · context
Insulin dosage was reduced by 30% from patients' usual estimates.
Report a problemFND-2604042903
04HumanRandomized controlled trialSafety outcome
In patients with type 1 diabetes receiving pramlintide with insulin, adverse events were infrequent and generally mild.
In plain wordsAdverse events were infrequent and generally mild in patients receiving pramlintide with insulin.
Peptide
Pramlintide (Symlin)
Outcome
Not applicableOverall adverse events
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
6, 9 or 12 mcg/unit insulin · injectionAs given in this study (human).
Source sentences
Summary
Adverse events were infrequent and generally mild.
2 context sentences(design, population, supporting numbers)
Summary · context
Patients with type 1 diabetes were enrolled in a randomized, single-masked, standard breakfast crossover study using regular human insulin injected simultaneously with pramlintide 6, 9 or 12 mcg/unit insulin or placebo.
Summary · context
Insulin dosage was reduced by 30% from patients' usual estimates.
Report a problemFND-2604042904

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 1NCT01708044

Effect of Different Fixed Pramlintide:Insulin Dose Ratios on Postprandial Glucose in T1DM

AstraZenecan = 32Nov 2012 to Sept 2013

Type 1 Diabetes

Trial page ClinicalTrials.govUpdated 20 Oct 2014

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.